Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach

被引:112
|
作者
Ito, K
Kusuhara, H
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan
关键词
oral absorption; CYP3A4; P-glycoprotein; diffusion model; drug interaction;
D O I
10.1023/A:1018872207437
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the effects of gut metabolism and efflux on drug absorption by simulation studies using a pharmacokinetic model involving diffusion in epithelial cells. Methods. A pharmacokinetic model for drug absorption was constructed including metabolism by CYP3A4 inside the epithelial cells, P-gp-mediated efflux into the lumen, intracellular diffusion from the luminal side to the basal side, and subsequent permeation through the basal membrane. Partial differential equations were solved to yield an equation for the fraction absorbed from gut to the blood. Effects of inhibition of CYP3A4 and/or P-gp on the fraction absorbed were simulated for a hypothetical substrate for both CYP3A4 and P-gp. Results. The fraction absorbed after oral administration was shown to increase following inhibition of P-gp. This increase was more marked when the efflux clearance of the drug was greater than the sum of the metabolic and absorption clearances and when the intracellular diffusion constant was small. Furthermore, it was demonstrated that the fraction absorbed was synergistically elevated by simultaneous inhibition of both CYP3A4 and P-gp. Conclusions. The analysis using our present diffusion model is expected to allow the prediction of in vivo intestinal drug absorption and related drug interactions from in vitro studies using human intestinal microsomes, gut epithelial cells, CYP3A4-expressed Caco-2 cells, etc.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 50 条
  • [21] Expression of P-glycoprotein and CYP3A4 along the porcine oral-gastrointestinal tract: implications on oral mucosal drug delivery
    Gao, Xiaoling
    Bhattacharya, Shiladitya
    Chan, William K.
    Jasti, Bhaskara R.
    Upadrashta, Bala
    Li, Xiaoling
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2014, 40 (05) : 599 - 603
  • [22] The barrier function of CYP3A4 and P-glycoprotein in the small bowel
    Watkins, PB
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 27 (2-3) : 161 - 170
  • [23] Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension
    Sun, Xiaoyu
    Tang, Shunxiong
    Hou, Binbin
    Duan, Zhijun
    Liu, Zhen
    Li, Yang
    He, Shoucheng
    Wang, Qiuming
    Chang, Qingyong
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [24] Short term effect of medications on CYP3A4 and P-glycoprotein expression in human intestinal mucosa
    Wille, RT
    Lown, KS
    Huszczo, UR
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1997, 112 (04) : A419 - A419
  • [25] Serum Rifampicin Levels in Patients with TuberculosisEffect of P-Glycoprotein and CYP3A4 Blockers on its Absorption
    Jai Prakash
    Thirumurthy Velpandian
    Jitender N. Pande
    Suresh K. Gupta
    Clinical Drug Investigation, 2003, 23 : 463 - 472
  • [26] P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
    Martinez-Chavez, Alejandra
    van Hoppe, Stephanie
    Rosing, Hilde
    Lebre, Maria C.
    Tibben, Matthijs
    Beijnen, Jos H.
    Schinkel, Alfred H.
    MOLECULAR PHARMACEUTICS, 2019, 16 (09) : 3842 - 3852
  • [27] Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats
    Li, C.
    Lee, M. Y.
    Choi, J. S.
    PHARMAZIE, 2010, 65 (07): : 510 - 514
  • [28] Potent in vitro Inhibition of CYP3A4 and P-Glycoprotein by Rhodiola rosea
    Hellum, Bent H.
    Tosse, Anita
    Hoybakk, Kathrine
    Thomsen, Mette
    Rohloff, Jens
    Nilsen, Odd Georg
    PLANTA MEDICA, 2010, 76 (04) : 331 - 338
  • [29] Effects of Silibinin, Inhibitor of CYP3A4 and P-Glycoprotein in vitro, on the Pharmacokinetics of Paclitaxel after Oral and Intravenous Administration in Rats
    Lee, Chong-Ki
    Choi, Jun-Shik
    PHARMACOLOGY, 2010, 85 (06) : 350 - 356
  • [30] St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
    Dürr, D
    Stieger, B
    Kullak-Ublick, GA
    Rentsch, KM
    Steinert, HC
    Meier, PJ
    Fattinger, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) : 598 - 604